Albireo Pharma Inc RPE
Quel est le RPE de Albireo Pharma Inc?
Le RPE de Albireo Pharma Inc est $441.469k
Quelle est la définition de RPE?
Le revenu par employé (RPE) est le revenu divisé par le nombre d'employés d'une organisation.
RPE des entreprises dans Health Care secteur sur NASDAQ par rapport à Albireo Pharma Inc
Que fait Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Entreprises avec rpe similaire à Albireo Pharma Inc
- Sanofi a RPE de €440.466k
- Sanofi a RPE de €440.466k
- Ashtead Plc a RPE de $440.641k
- Baofeng Modern International a RPE de ¥440.836k
- GreenSky Inc a RPE de $441.290k
- The Heavitree Brewery PLC a RPE de £441.375k
- Albireo Pharma Inc a RPE de $441.469k
- SB Inc a RPE de $441.496k
- LendingTree a RPE de $441.727k
- Yu Tak International a RPE de HKD$441.739k
- Jiumaojiu International a RPE de ¥441.807k
- Anaergia Inc a RPE de CAD$441.932k
- AMG Advanced Metallurgical NV a RPE de $441.948k